Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791258 · ClinicalTrials.gov registry record · Phase 4
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
A Phase 4 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 999
- Enrollment target
NCT00791258 is a Phase 4 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 999 participants.
The verdict
NCT00791258, a Phase 4 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 999 participants
- Enrollment target
Study Summary
The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.
Interventions
- DRUG amlodipine and olmesartan medoxomil tablets
- DRUG hydrochlorothiazide tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791258
The ClinicalTrials.gov registry entry for NCT00791258 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 999 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which amlodipine and olmesartan medoxomil tablets is the first listed.
NCT00791258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791258 about?
NCT00791258 is a clinical study titled "A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure". The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The...
What is the current status of trial NCT00791258?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 999 participants. The study started on 2008-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00791258?
The interventions under investigation include: amlodipine and olmesartan medoxomil tablets (DRUG), hydrochlorothiazide tablets (DRUG).
Who is sponsoring clinical trial NCT00791258?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.